HORAMA aims being one of the key players in the field of ophthalmic gene therapy

HORAMA is one of the key players in the field of ophthalmic gene therapy.

HORAMA develops new gene therapies for rare inherited ocular diseases to improve or restore patient autonomy and reduce healthcare costs for society. The objective of replacement gene therapy is to provide a non-mutated copy of the causative mutated gene.

HORAMA approach is based on vector technology using non-pathogenic, recombinant adeno-associated viruses (rAAV). The rAAV carrying the therapeutic gene of interest penetrates the target retinal cells, inducing the expression of the functional protein. This restores normal cell function, prevents further retinal deterioration, and improves or restores visual function.

ophthalmic gene therapy

HORAMA has developed and optimised proprietary manufacturing processes in collaboration with its academic partners.

The HORAMA platform can support a pipeline of innovative gene therapy products for several ocular diseases.

HORAMA has signed exclusive licensing agreements on several patent applications and on non-clinical and clinical (Phase I/II) know-how. In addition, HORAMA has been granted Orphan Drug Designations for each of its products, providing incentives from Health Authorities and a market exclusivity of 7 to 10 years.


Fact sheet- HORAMA 2017



Horama does not own any office in Australia.

The company was warned that someone, claiming to be Christine Placet or Christen Placet, had contacted australian job seekers.

If you see a job offer matching this description, do not answer.

Horama has filed a complaint.